



Dear colleague,

It is with great pleasure to invite you for the First International Symposium “*Current and Future Perspectives in Primary Liver Tumors*” which will be held in Rotterdam, the Netherlands, from August 31 to September 1, 2017. This multidisciplinary Symposium will be organized by the Erasmus MC, University Medical Center Rotterdam, under the auspices of the International Association of Surgeons, Gastroenterologists, and Oncologists (IASGO).

We especially invite surgeons, hepatologists, radiologists and oncologists to take part in our symposium. Our symposium is intended as educational and networking event. It will provide a comprehensive overview of the current status and developments in the diagnostic and treatment of primary liver tumors.

There will be great opportunities to interact with the expert faculty during the symposium and during networking event. The symposium will be held in a unique location of former Holland-America Line Cruise Ship SS Rotterdam, which has been converted to a hotel and a meeting venue with splendid views on Rotterdam and its skyline.

Last but not least: for those who want to spend a fantastic weekend in Rotterdam after the symposium, there is a great opportunity to experience a spectacular festival – the World Port Days (www.wereldhavendagen.nl) held each year in the first weekend of September.

For inquiries, please contact us at: HPBrotterdam@erasmusmc.nl

Looking forward to see you in Rotterdam!

On behalf of the local organizing committee,

Jan IJzermans
Chairman

Masatoshi Makuuchi
President of IASGO

Registration fee: 280,- EUR for non members, 140,- EUR for IASGO members, fellows and residents.
Accreditation: UEMS/EACCME, Nederlandse Vereniging voor Heelkunde (NVvH), Nederlandse Vereniging voor Maag-Darm-Leverartsen, Nederlandse Vereniging Voor Radiologie (NVVR), Nederlandse Vereniging voor Chirurgische Oncologie (NVCO), Verpleegkundig Specialisten Register (V&VN), Nederlandse Associatie Physician Assistants (NAPA)
Workshop language: English

Information:

Ms. Carla Loeff
HPBrotterdam@erasmusmc.nl
+31 (0)10 703 18 10

Address:

Division of HPB and Transplant Surgery
Department of Surgery
Erasmus MC
PO Box 2040, 3000 CA Rotterdam
The Netherlands

Venue/Hotel:

SS Rotterdam
3e Katendrechtsehoofd 25
3072 AM Rotterdam
+31 (0)10 297 30 90
info@ssrotterdam.nl
www.ssrotterdam.com/erasmus-mc-symposium-2017

Registration:

www.erasmusmc.nl/chirurgie

Organizing Committee:

Jan IJzermans
Rob de Man
Herold Metselaar
Adriaan Moelker
Wojciech Polak
Dave Sprengers
Khe Tran

IASGO Executive Board:

Masatoshi Makuuchi, *President*
Norihiro Kokudo, *Vice President*
Irinel Popescu, *Vice President*
Kyoichi Takaori, *Secretary General*
Dan G. Duda, *Secretary General*
Ho-Seong Han, *Treasurer*
Guido Torzilli, *Editor-in-Chief*



Symposium Current and Future Perspectives in Primary Liver Tumors

August 31st – September 1st 2017
Rotterdam, The Netherlands

August 31st - September 1st 2017

DAY 1 - Thursday (August 31, 2017)	
11.15–11.45	Welcome Reception
11.45–12.00	Welcome address Jan IJzermans, Rotterdam, The Netherlands Rob de Man, Rotterdam, The Netherlands
12.00–14.00	SESSION 1 Hepatocellular Carcinoma
Chairs:	Massimo Colombo, Milan, Italy Rob de Man, Rotterdam, The Netherlands
12.00–12.30	Epidemiology and screening of HCC Massimo Colombo, Milan, Italy
12.30–13.00	Accuracy of imaging modalities Francois Willemsen, Rotterdam, The Netherlands
13.00–13.30	BCLC criteria vs other prognostic systems for HCC patients. Western perspective Umberto Cillo, Padova, Italy
13.30–14.00	Predicting HCC development Philip Johnson, Liverpool, UK
14.00–14.30	Coffee break
14.30–16.30	SESSION 2 Surgical Treatment for HCC
Chairs:	Masatoshi Makuuchi, Tokyo, Japan Wojciech Polak, Rotterdam, The Netherlands
14.30–15.00	Risk assessment before liver surgery for HCC in cirrhotic patients Thomas van Gulik, Amsterdam, The Netherlands
15.00–15.30	Boundaries in liver resection for HCC Masatoshi Makuuchi, Tokyo, Japan
15.30–16.00	Deceased donor liver transplantation for HCC Rene Adam, Paris, France
16.00–16.30	Living donor liver transplantation for HCC Dieter Broering, Riyadh, Saudi Arabia
16.30–17.00	Coffee break

DAY 2 - Friday (September 1, 2017)	
17.00–18.30	SESSION 3 Loco-regional Treatment in HCC
Chairs:	Bruno Sangro, Navarro, Spain Turkan Terkivatan, Rotterdam, The Netherlands
17.00–17.30	Advances and limitations in ablation techniques for HCC Otto van Delden, Amsterdam, The Netherlands
17.30–18.00	Transarterial radioembolisation - how does it affect our daily practice Bruno Sangro, Navarra, Spain
18.00–18.30	The role of TACE in the SIRT era Adriaan Moelker, Rotterdam, The Netherlands
19.30–22.30	Networking
08.30–10.30	SESSION 4 Emerging Therapies for HCC
Chairs:	Alejandro Forner, Barcelona, Spain Khe Tran, Rotterdam, The Netherlands
08.30–09.00	Radiotherapy for HCC Thomas Brunner, Freiburg, Germany
09.00–09.30	Is proton therapy the new radiotherapy for HCC? Alejandra Mendez Romero, Rotterdam, The Netherlands
09.30–10.00	Immunotherapy in the treatment of HCC Dave Sprengers, Rotterdam, The Netherlands
10.00–10.30	Progress in systemic therapy of advanced HCC Alejandro Forner, Barcelona, Spain
10.30–11.00	Coffee break

DAY 3 - Saturday (September 2, 2017)	
11.00–13.30	SESSION 5 Innovations in Liver Tumor Diagnostics
Chairs:	Dan G. Duda, Boston, USA Jan IJzermans, Rotterdam, The Netherlands
11.00–11.30	Radiomics and liver tumors Martijn Starmans, Rotterdam, The Netherlands
11.30–12.30	Translation from molecular biology to clinical practice Jessica Zucman-Rossi, Paris, France
12.30–13.00	The role of translational studies in clinical trials of liver cancers Dan G. Duda, Boston, USA
13.00–13.30	Personalised approach using organoids in the treatment of liver tumors Meritxell Huch, Utrecht, The Netherlands
13.30–14.30	Lunch
14.30–16.30	SESSION 6 Cholangiocarcinoma
Chairs:	Christian Toso, Geneva, Switzerland Jeroen de Jonge, Rotterdam, The Netherlands
14.30–15.00	Epidemiology of hilar cholangiocarcinoma Sarwa Darwish Murad, Rotterdam, The Netherlands
15.00–15.30	Difficulties in preoperative tumor assessment in hilar cholangiocarcinoma Bas Groot Koerkamp, Rotterdam, The Netherlands
15.30–16.00	Surgical treatment of hilar cholangiocarcinoma Christian Toso, Geneva, Switzerland
16.00–16.30	Advances in systemic therapy for cholangiocarcinoma Arndt Vogel, Hannover, Germany
16.30–16.45	Closing remarks
16.45	Farewell